Catalent Creates Business Unit Biologics Development

Catalent Pharma Solutions (Somerset, NJ) has created a business unit dedicated to helping customers bring new pharmaceutical and biologic products to market. The Development and Clinical Services segment brings together Catalent's analytical and science services and regulatory consulting services, formerly in its Sterile Technologies segment, with its clinical supply services business, formerly included in the Packaging Services segment. Catalent has appointed Scott Houlton group president for the new segment.

The new segment will build on Catalent's experience supporting the development and testing of drugs and biologics through scientific, regulatory, and clinical trial supply chain services. Catalent provides services, extending from the first steps characterizing a drug molecule to delivery of drugs to the investigator site through the final submission of regulatory filings. For biologics, Catalent's offerings include bioanalytical services, the GPEx technology and cell-line development services, biomanufacturing, and specialized cold chain distribution for clinical trial materials. The new segment provides global regulatory consulting and support, respiratory delivery formulation, development and manufacture, and early phase injectables manufacture.

Houlton most recently served as the chief operating officer of Aptuit, Inc., and before that as president of Aptuit's clinical packaging business. Before Aptuit, Houlton held several leadership roles in the development service business of Quintiles Transnational, with previous experience at Cardinal Health and General Electric.